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Abstract: The present study aimed to screen plants for bioactive compounds with potential
antibacterial activities. In our efforts to evaluate plants from Borneo, we isolated
and elucidated the structures of four natural products from the bioactive fraction of a
chloroform extract of Goniothalamus longistipetes using various chromatographic and spectroscopic
techniques. The bioactive compounds were identified as a known styryllactone, (+)-altholactone
((2S,3R,3aS,7aS)-3-hydroxy-2-phenyl-2,3,3a,7a-tetrahydrobenzo-5(4H)-5-one) (1), a new styryllactone,
(2S,3R,3aS,7aS)-3-hydroxy-2-phenyl-2,3,3a,7a-tetrahydrobenzo-5(4H)-5-one) (2) as well as a new
alkaloid, 2,6-dimethoxyisonicotinaldehyde (3) and a new alkenyl-5-hydroxyl-phenyl benzoic acid (4).
1 and 4 showed broad-spectrum anti-bacterial activities against Gram-positive and Gram-negative
bacteria as well as acid-fast model selected for this study. Compound 2 only demonstrated
activities against Gram-positive bacteria whilst 3 displayed selective inhibitory activities against
Gram-positive bacterial strains. Additionally, their mechanisms of anti-bacterial action were
also investigated. Using Mycobacterium smegmatis as a fast-growing model of tubercle bacilli,
compounds 1, 2 and 4 demonstrated inhibitory activities against whole-cell drug efflux and biofilm
formation; two key intrinsic mechanisms of antibiotic resistance. Interestingly, the amphiphilic
compound 4 exhibited inhibitory activity against the conjugation of plasmid pKM101 in Escherichia
coli using a plate conjugation assay. Plasmid conjugation is a mechanism by which Gram-positive
and Gram-negative-bacteria acquire drug resistance and virulence. These results indicated that
bioactive compounds isolated from Goniothalamus longistipetes can be potential candidates as ‘hits’ for
further optimisation.
Keywords: Goniothalamus longistipetes; Annonaceae; antibacterial; efflux pumps; biofilm formation;
bacterial conjugation; furo-pyrenone; styryllactones; alkaloid; alkenyl-hydroxybenzoic acid
1. Introduction
The search for and use of drugs derived from natural sources has furnished mankind with a
rich and important source of therapeutic agents. For instance, Newman et al. [1] reported that from
1981 to 2002, 75% of all the anti-infective drugs approved for use were derived from natural sources.
Additionally, 61% of all new chemical compounds introduced globally as drugs during the same period
were derived from, or were inspired by natural products [2]. Plants have been a source of antibiotics in
both ancient and modern times [3].
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With the emergence of multi-drug-resistance in WHO-priority bacterial pathogens, the search for
new and more effective cures is imperative [4]. Resistance to antimicrobials is a growing and significant
problem and affects treatment options. As many existing antibiotics or their synthesized derivatives
become ineffective as a result of resistance, antimicrobials and other compounds derived from plants
can offer an alternative and novel source [5].
The tropical rain forests of Borneo are one of the global hotspots for plant biodiversity, many of
which have traditional uses. Although there is no specific information on ethnobotanical uses for
Goniothalamus longistipetes which can be attributed to the rareness of this endemic species, other more
widespread species of the genus Goniothalamus from the Annonaceae family are known to possess
ethnobotanical uses in Borneo including as folkmedicines [6,7]. Wiart [8] and Muhammad et al., [9]
have reviewed Goniothalamus phytochemistry for antibacterial properties and both noted that the genus
was poorly studied but with potential for antibacterial compounds whilst the main phytochemicals
isolated were styryllactones [8,9] and acetogenins [8,10]. In this study, we screened the stem bark
of Goniothalamus longistipetes for these activities and report the structures and potential antibacterial
action of the compounds.
2. Results
2.1. Phytochemistry
The bioactive fraction of the chloroform extract of Goniothalamus longistipetes gave a known (1)
and new styryllactone (2) as well as a new pyridine alkaloid (3) and a new alkenyl-5-hydroxy-phenyl
benzoic acid (4) (Figure 1).
Figure 1. Compounds isolated from Goniothalamus longistipetes—a known styryllactone, (+)-altholactone
((2S,3R,3aS,7aS)-3-hydroxy-2-phenyl-2,3,3a,7a-tetrahydrobenzo-5(4H)-5-one) (1), a new styryllactone,
(2S,3R,3aS,7aS)-3-hydroxy-2-phenyl-2,3,3a,7a-tetrahydrobenzo-5(4H)-5-one) (2) as well as a new
alkaloid, 2,6-dimethoxyisonicotinaldehyde (3) and a new alkenyl-5-hydroxyl-phenyl benzoic acid (4).
A full structure elucidation of these compounds is presented in the Supplementary Materials
(Figures S1–S33; Tables S1–S4). Compound 1 was identified by comparison of its 1H, 13C and mass
spectral data with that of the literature [11]. The structures of 2–4 were determined by full 2D nmR
analysis, particularly using HMBC spectroscopy. In addition to these techniques, for compound 4,
the position of the double bond was identified by derivatization and comparison of fragments with a
mass spectral library, confidently allowing placement of the double bond between C-8 and C-9.
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2.2. Antibacterial Activities
Compounds 1 and 4 showed broad-spectrum anti-bacterial activities against Gram-positive,
Gram-negative as well as acid-fast mycobacterial strains selected for this study, while 2 demonstrated
activities only against Gram-positives and a strain of Mycobacterium sp. 3 exhibited specific inhibitory
activities against Gram-positive bacterial strains. The anti-bacterial activities of all the compounds and
their respective selective indices are listed in Table 1. For the broth dilution assay for Gram-positive and
negative-bacteria, inhibitors were serially (2-fold) diluted with a starting concentration of 512 µg/mL
whilst for the acid-fast mycobacterial strains, a serial dilution ranging from 500 µg/mL to 0.0224 µg/mL
was carried out.
Table 1. Antibacterial (MIC) and cytotoxic (IC50) activities of compounds 1–4 and their respective
selectivity indices (S.I.).































































































Compound 1 exhibited more toxicity to the eukaryotic cell-line (RAW 264.7) compared to bacterial
cells (Table 1: selectivity indices/S.I. < 1) except for M. bovis BCG, a slow-growing model of M. tuberculosis.
We can infer from this result that compound 1 is selective (Table 1: selectivity indices/S.I. = 4) in
inhibiting slow-growing mycobacterial growth. Compound 2 was found to be selective for inhibiting
growth of all strains of Staphylococcus sp. (Table 1: selectivity indices/S.I. = 3.91) used in this study.
Whereas compound 2 was found to be equally toxic to the eukaryotic cell when it was tested against
the Gram-negative and mycobacterial species. Interestingly, compound 3 was selectively potent
(Table 1: selectivity indices/S.I. = 3.91) against the Bacillus subtilis strain. Compound 4 displayed the
best selective inhibitory growth against the Gram-positive and acid-fast strains (Table 1: selectivity
Antibiotics 2020, 9, 913 4 of 11
indices/S.I. = 16–32). In this whole-cell drug susceptibility assay, the mouse macrophage cell line
(RAW 264.7) was used for the evaluation of toxicity against eukaryotic cells.
2.3. Drug Accumulation and Inhibition of Biofilm Formation Assays
Efflux pumps and biofilm formation are two important mechanisms by which bacteria develop
resistance to antibiotics. The results of the accumulation assay and the biofilm formation assay for
compounds 1, 2 and 4 are shown in Figure 2. Compounds 1, 2 and 4 displayed inhibitory activities
in the whole cell phenotypic accumulation assay using M. smegmatis as a model when compared
to the controls demonstrating that the compounds can inhibit the efflux pumps. For the biofilm
inhibition assay, the three compounds also exhibited inhibitory activities (p-value < 0.01) at both the
concentrations for MIC and their respective sub-inhibitory concentrations (half that of MICs) when
compared with their respective controls. For the accumulation assay, EtBr was used as a known
substrate for whole cell efflux pumps and the two known efflux pump inhibitors, verapamil and
chlorpromazine, were used as controls whilst for the biofilm inhibition assay, a negative control was
employed. DMSO was also used to see if there was any effect on biofilm inhibition, because DMSO
was used as the solvent to dissolve the compounds tested.
Figure 2. Inhibitory activities by compound (a) 1, (b) 2 and (c) 4 in both the accumulation (left)
using 3 replicates (coefficient of variation, cv < 1) and biofilm formation (right ) using 6 replicates
(p-value < 0.01) assays. Blue line: verapamil (0.5×MIC)—A—negative control; Red line: chlorpromazine
0.5 ×MIC—B—DMSO; Green line: compound with no known activity (0.5 ×MIC)—C—0.5 ×MIC;
Purple line: compound tested for activity (0.5 ×MIC); Black line: drug-free control.
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2.4. Plate Conjugation Assay
Apart from efflux pumps and biofilm formation, another mechanism that contributes to drug
resistance in bacteria is plasmid conjugation. Bacteria can disseminate plasmids harbouring genes
responsible for drug resistance to other bacteria through plasmid conjugation [12]. Inhibitor of bacterial
conjugation for specific plasmids such as pKM101 can therefore be of use to reduce drug resistance.
Amphiphilic compounds are known to inhibit bacterial plasmid conjugation and as compound 4 is
amphiphilic, a plate conjugation assay [12] was carried out in order to determine its inhibitory effect
on bacterial plasmid conjugation in Escherichia coli.
In order to discern between antibacterial activity and the inhibition of plasmid conjugation,
compound 4 was assessed at a quarter of its MIC value (256 µg/mL) for this assay. A negative control
was employed. Plasmid pKM101 (donor strain) confers resistance to amoxicillin whilst the recipient
strain ER1793 is resistant to streptomycin. Subculturing onto media containing amoxicillin and
streptomycin allows determination of transconjugation. So, each strain was subcultured in its selective
media based on resistance characteristics. The experiment was repeated three times. The results of the
conjugation assay are shown in Figure 3. Based on the result of the transconjugant bacterial colony
count as well as the donor colony count in the control, there was an approximately 70% reduction in
plasmid conjugation when compared to the control (p < 0.05) (Figure 4) indicating that compound 4
might be able to inhibit plasmid conjugation.
Figure 3. Result of the plate conjugation assay showing the transconjugant cells for 4 with a concentration
of a quarter of MIC and control using plasmid pKM101 in E. coli.
Figure 4. Bar graph showing the inhibitory activity on pKM101 plasmid conjugation of compound 4 in
E. coli when compared with the control (p < 0.05). The transfer frequency is expressed as the number of
transconjugants per donor cell obtained from mating.
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3. Discussion
There are few studies done on the antibacterial properties for chemical constituents isolated
from species of Goniothalamus. Styryllactone, altholactone, and previously isolated from G. malayanus
showed moderate broad-spectrum activities against Gram-positive and Gram-negative bacteria except
Pseudomonas aeruginosa [13] which is consistent with the results from our study. Another stereoisomer
of compound 1, isoaltholacthone, isolated from Goniothalamus grandifolius (not isolated from this study)
also displayed broad-spectrum activities [14]. For the pyrimidine alkaloid (3) isolated in this study
and for the first time from Goniothalamus, specific activities against strains of Gram-positive bacteria
were only observed. Previously, only aristolactam alkaloids have been isolated from Goniothalamus
velutinus, which did not show any antibacterial activities [15]. Studies on the mechanisms of action of
antibacterial compounds from Goniothalamus have been neglected.
The results of the inhibitory activities in the accumulation assay for compounds 1, 2 and 4 (Figure 3)
indicated that they were able to inhibit efflux pumps. In addition, all three compounds could also
inhibit the formation of biofilms using M. smegmatis as a model and there is a correlation with efflux
pump inhibition. There is evidence from several studies that have shown that efflux pumps also play a
significant role in biofilm formation [16]. Kvist et al. [17] demonstrated in E. coli that the inactivation
of efflux pumps resulted in the failure to form a bacterial biofilm. The downregulation in particular
of, the AdeFGH efflux pump, is probably responsible for a decrease in the formation of biofilm in
Acinetobacter baumannii treated with tigecycline below inhibitory concentrations [18]. Aristolactam
alkaloids from Goniothalamus velutinus have been shown to possess selective inhibitory activities on
biofilm formation of some selected Gram-positive and Gram-negative bacterial species [17].
Because there is a correlation between efflux pumps and inhibition of biofilm, inhibitors of efflux
pumps could potentially act as inhibitor of biofilm formation. By understanding the roles that efflux
pumps play in biofilm formation, it is possible that novel therapeutic strategies can be developed to
inhibit and interfere with biofilms and therefore improve the treatment of bacterial infections [18].
Stereoisomers 1 and 2 showed differing activities against Gram-positive, Gram-negative and
acid-fast mycobacterial strains. However, both stereoisomers did not show much difference in their
activities against the two effluxing strains (XU212 and SA1199B) for S. aureus when compared with
the susceptible strain (SA25923), indicating that they might not be able to inhibit the efflux pumps in
both strains. The overexpression of efflux pumps in XU212 is coded by the tet(K) gene [19] and causes
resistance to the antibiotic tetracycline while in SA1199B, it is coded by the norA gene which causes
overexpression of the NorA efflux pump and therefore resistance to the antibiotic norfloxacin and both
efflux pumps belong to the Major Facilitator Superfamily (MFS) family [20]. However, in the whole cell
phenotypic accumulation assay using Mycobacterium smegmatis, there were good activities shown by
both styryllactone isomers. This could mean that the compounds inhibit efflux pumps other than those
in the MFS family, because Mycobacterium smegmatis is known to possess all 5 families of efflux pumps.
The pKM101 plasmid belongs to the IncN plasmid family, and is a 35.4kb derivative from the
parent R46 [21]. It renders E. coli and S. typhimurium resistant to the effects of UV radiation and
mutagenesis [21]. The DNA region of R46, when removed in vivo, removed the gene coding for
resistance to sulphonamides, streptomycin, and spectinomycin but conferred the ability of pKM 101
to increase resistance to UV as well as the presence of ampicillin resistance and the fertility factor of
E. coli [22].
The result from the plate conjugation assay for compound 4 showed a reduction in the plasmid
conjugation by about 70%. This demonstrated that the compound which is amphiphilic might be able to
inhibit the conjugation process (e.g.,Type-IV secretory systems (T4SS)) or the horizontal transfer of the
plasmid [21] that carried the resistance gene (pKM101) which is resistance to amoxicillin. The mechanism
behind the inhibition of plasmid conjugation by 4 was not investigated. However, compounds very
similar to compound 4 (5-alkyl resorcinols) isolated from the Australian plant, Hakea amplexicaulis,
were found to be able to cleave DNA in the presence of Cu2+ [22]. Type-IV secretion systems (T4SS)
are important secretion systems or ‘molecular syringes’ that are found in both Gram-positive and
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Gram-negative bacteria and secrete a wide range of substrates, from single proteins to protein–protein
and protein–DNA complexes into other cells in order to manipulate and often kill rival bacterial
and eukaryotic cells. [21,23]. The horizontal gene transfer conferred by T4SS is also one of the main
mechanisms for the spread of genes responsible for resistance to antibiotics as well as virulence
factors in a variety of human diseases such as whooping cough (Bordetella pertussis) and peptic and
gastric cancers [24]. Plasmids carry resistance genes which are separated from and can replicate
independently of the bacterial chromosomal DNA and can, therefore, render resistance to one or more
antibiotics [24–26]. Plasmids are commonly able to transfer between bacterial cells from different
species by a mechanism known as conjugation, which involves cell-to-cell contact followed by transfer
of a copy of plasmid DNA from a donor to a recipient [23]. The spread of multiple antimicrobial
resistance has been enhanced by selective pressure from human and veterinary medicine [27].
4. Materials and Methods
4.1. General Experimental Procedures
One- and two-dimensional (1D and 2D) nmR spectra were recorded on a 500 MHz spectrometer
(Bruker) using tetramethylsilane as internal references with referencing to solvent signals (CDCl3).
UV and IR spectra were recorded on a Thermo Electron Corporation Helios spectrophotometer and
on a Nicolet 360 FT-IR spectrophotometer respectively. Mass spectra were recorded using HRESIMS
for accurate mass determination (m/z value up to four decimal places) and were performed using
a Waters Quadrupole/Time of flight (Q-ToF) premier Tandem Mass Spectrometer and a Shimadzu
LCMS-2020 which is a single quadrupole mass spectrometer with a mass range of 50 Da to 2000 Da.
Chemical and biological reagents were obtained from Sigma Aldrich Company Ltd., Dorset, UK unless
otherwise stated.
4.2. Plant Materials
The bark of G. longistipetes (approximately 0.5 kg) was obtained in Sarawak, Malaysia in
February 2013. The plant specimen was identified at the Forest Herbarium, Forest Research Centre,
Forest Department Sarawak, Malaysia and a voucher specimen (S.90) was kept at the Forest Herbarium
as well as the herbarium at the School of Pharmacy, University College London.
4.3. Extraction and Isolation
The pulverized bark of G. longistipetes was extracted in the sequential order—hexane and
chloroform and methanol using the Soxhlet apparatus. The respective crude extracts were concentrated
and dried by means of a rotatory evaporator and blow down under nitrogen gas and then fractionated
by Vacuum Liquid Chromatography (silica gel with 100–200 mesh as stationary phase) into 13 fractions
using a mixture of two solvents in increasing order of polarity. Preparative-TLC (prep-TLC) was done
on the fractions based on the activities in the biological assay using a full normal-phase silica sheet gel
60 F254 (Merck KGaA).The TLC plate was then air dried in a flow hood and viewed under short UV
(254 nm) and long UV (356 nm) light (Camag) as well as sprayed with appropriate stains to locate the
compounds. The respective bands were then scratched off the plate and the compounds were obtained
by desorption using a solvent appropriate for the pure compounds.
4.4. Bacterial Strains and Drug Susceptibility Assays
Broth dilution assay [28] was used for Gram-positive and Gram-negative bacteria while spot culture
growth inhibition assay (SPOTi) [29,30] was employed for acid-fast strains. The Gram-positive bacterial
strains used were Staphylococcus aureus: SA25923 (susceptible strain), XU212 (tetracycline-resistant),
SA1199B (norfloxacin-resistant), eMRSA-15 (methicillin-resistant) and one Bacillus species: Bacillus subtilis
(a susceptible strain) whilst 3 susceptible strains of Gram-negative bacteria were E. coli NCTC 10418,
Pseudomonas aeruginosa and Klebsiella pneumoniae NCTC 10662.
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For mycobacteria, Mycobacterium smegmatis mc2155 (fast growing) and Mycobacterium bovis BCG
Pasteur ATCC35734 (slow growing) species were used in this study. A serial dilution in a 96-well
microtiter plate was done for the compounds in DMSO.
4.5. Eukaryotic Cytotoxicity Assay
Mammalian cells (mouse macrophage RAW 264.7 (ATCC TIB71)) used in the cytotoxicity assay
were a kind gift from Professor Simon Gordon, University of Oxford. The rezazurin assay method
was employed for the cytotoxicity assay [31]. The 90% growth inhibitory concentration (GIC90) was
ascertained and the selectivity index (SI), was determined as the ratio between the GIC90 on RAW 264.7
mouse macrophages and the MIC on the respective bacterial strain. For example, the SI = GIC90/MIC.
Paclitaxel was used as the control for the cytotoxic assay.
4.6. Accumulation Assay
The accumulation assay was conducted using the whole cell phenotypic assay with Mycobacterium
smegmatis mc2 122 cells as the model. The method used followed that employed by [32]. Verapamil
(final working concentration of 12.5 µg/mL) and chlorpromazine (final working concentration of
15.6 µg/mL) were the positive efflux pump inhibitory controls together with a drug-free control in the
assay. All the test samples and blanks were prepared in triplicate. The continuous live monitoring
of the florescence was done, a cycle of measurement every 60 s for a total period of 60 min, using a
plate reader (FLUOstar OPTIMA, BMG Labtech, Manchester, UK) with the settings as follows; 540 and
590 nm for excitation and detection of fluorescence (emission).
4.7. Biofilm Assay
The biofilm assay followed the method applied by [33] by means of the whole cell phenotypic assay
using M. smegmatis mc2 122 as a model. Compounds at the concentrations of MICs and sub-inhibitory
concentration (half of MICs) were tested. In addition, experiments using DMSO at the concentration
used to dissolve the tested compounds were also used to determine if there was any effect on biofilm
formation. Additionally, a negative experiment was also set up.
4.8. Plate Conjugation Assay
The plate-conjugation assay used the broth mating method as employed by [12]. Two bacterial
strains of E. coli were used in this assay for the plasmid conjugation assay, as shown in Table 2.
Table 2. The donor and recipient strains used in the conjugation study.
Donor Strain Plasmid Resistance Marker Recipient Strain Resistance Marker
WP2 pKM101 Amoxicillin ER1793 Streptomycin
The ER1793 strain was used as the recipient (streptomycin-resistant) whilst the pKM101-containing
strain was the donor (amoxicillin-resistant). The plate conjugation assay used MacConkey agar
supplemented with amoxicillin to facilitate identification of donor cells, and agar containing amoxicillin
and streptomycin to distinguish transconjuants. The number of transconjugants to donor cells were
used to determine the conjugation frequencies. Conjugation efficacy was calculated based on the
conjugation frequencies expressed as a percentage relative to the control.
4.9. Statistical Analyses
All statistical analyses were computed using Microsoft Excel 2010 or GraphPad prism. The coefficient
of variation (cv) was calculated as a ratio of the standard deviation to the mean with the data obtained
from the 3 replicates (no outlier if cv < 1) whilst the p-value was carried out by comparing the means of
each experiment using independent t-test (significant difference if p-value < 0.05).
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5. Conclusions
This study highlighted the potential of bioactive compounds from Goniothalamus longistipetes with
reasonably good activities as drug ‘hits’. Compound 1 as well as 2 and 3 can be further optimized
especially against the slow-growing mycobacterium and Gram-positive bacterial strains respectively
whilst the broad-spectrum compound 4 deserves further investigation and development for its
inhibitory activities on the 3 key resistance determinants.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/12/913/s1,
Figure S1: 1H nmR spectrum of 1 in CDCl3 (500 MHz); Figure S2: 1H nmR spectrum of 1 (expanded) in CDCl3
(500 MHz); Figure S3: 1H nmR spectrum of 1 (expanded) in CDCl3 (500 MHz); Figure S4: 13C nmR spectrum
of 1 in CDCl3 (500 MHz); Figure S5: Expansion of HMQC spectrum of 1 in CDCl3; Figure S6: Expansion of
HMBC spectrum of 1 in CDCl3; Figure S7: Expansion of COSY spectrum of 1 in CDCl3; Figure S8: ESI-MS
spectrum of 1 showing peak ion at m/z 238.1 [M-H]- (indicated by arrow); Figure S9: 1H nmR spectrum of 2 in
CDCl3 (500 MHz); Figure S10: 1H nmR spectrum of 2 in CDCl3 (500 MHz); Figure S11: 1H nmR spectrum of 2
in CDCl3 (500 MHz); Figure S12: 13CNMR spectrum of 2 in CDCl3 (125 MHz); Figure S13: HMQC spectrum of
2 in CDCl3; Figure S14: HMBC spectrum of 2 in CDCl3; Figure S15: COSY spectrum of 2 in CDCl3; Figure S16:
HRMS spectrum of 2 showing peak ion at m/z 255.0627; Figure S17: 1H nmR spectrum of 3 in CDCl3 (500 MHz);
Figure S18: 13C spectrum of 3 in CDCl3 (125 MHz); Figure S19: 13C spectrum of 3 in CDCl3 (125 MHz); Figure S20:
HMQC spectrum of 3 in CDCl3; Figure S21: HMBC spectrum of 3 in CDCl3; Figure S22: COSY spectrum of 3
in CDCl3; Figure S23: ESI-MS spectrum of 3 showing peak ion at m/z 166.0 (indicated by arrow); Figure S24:
1H nmR spectrum of 4 in CDCl3 (500 MHz); Figure S25: 13C nmR spectrum of 4 in CDCl3 (125 MHz); Figure S26:
13C nmR spectrum of 4 (expanded) in CDCl3 (125 MHz); Figure S27: HMQC spectrum of 4 in CDCl3; Figure S28:
HMBC spectrum of 4 in CDCl3; Figure S29: COSY spectrum of 4 in CDCl3; Figure S30: HRMS spectrum of 4
showing peak ion at m/z 373.2732; Figure S31: The EI mass spectrum of the GC peak corresponding to the alkenyl
chain of 4 as identified from the NIST database (fragmentation pattern proposed as oleic acid trimethylsilyl acid);
Figure S32: Preparation of dimethyl disulphide derivatives; Figure S33: Derivatisation of the hydroxyl groups;
Table S1: 1H (500 MHz) and 13C nmR (125 MHz) and HMBC spectroscopic data of 1 recorded in CDCl3 compared
with published data; Table S2: Comparison of the hydrogen chemical shifts and coupling constants between 2
with 3 other known styryllactones; Table S3: 1H (500 MHz) and 13C nmR (125 MHz) and HMBC spectroscopic
data of 2 recorded in CDCl3; Table S4:. 1H (500 MHz),13C nmR (125 MHz) and HMBC spectroscopic data of 3 and
4 recorded in CDCl3.
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